Role of lipopolysaccharide in the induction of type I interferon-dependent cross-priming and IL-10 production in mice by meningococcal outer membrane vesicles

Vanessa Durand, Joanne MacKenzie, Joel de Leon, Circe Mesa, Valerie Quesniaux, Maria Montoya, Agnes Le Bon, Simon Y C Wong

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We investigated the contribution of lipopolysaccharide (LPS) to adjuvant properties of native outer membrane vesicles (NOMV), a vaccine candidate for meningococcal B disease. NOMV induce the maturation of and cytokine production by murine bone marrow-derived dendritic cells through both toll-like receptors (TLR) 2 and 4 which are mostly dependent on the signalling adaptor MyD88. NOMV are also able to induce B cell proliferation in splenocytes from LPS-hyporesponsive mice. However, induction of IL-10 and type I interferon-dependent, antigen-specific and IFN¿-secreting CD8+ cytotoxic T lymphocyte responses in vivo by NOMV requires LPS. The importance of LPS in the induction of IL-10 and functional cross-priming has implications for NOMV-based vaccine and adjuvant development.
Original languageEnglish
Pages (from-to)1912-1922
Number of pages11
JournalVaccine
Volume27
Issue number13
Early online date31 Jan 2009
DOIs
Publication statusPublished - 18 Mar 2009

Fingerprint

Cross-Priming
Interferon Type I
interferons
interleukin-10
Interleukin-10
lipopolysaccharides
Lipopolysaccharides
Membranes
mice
adjuvants
vaccines
cytotoxic T-lymphocytes
Meningococcal Vaccines
dendritic cells
Toll-Like Receptor 2
splenocytes
Toll-Like Receptor 4
bone marrow
B-lymphocytes
Cytotoxic T-Lymphocytes

Keywords

  • lipopolysaccharide
  • meningococcal disease
  • cross-priming

Cite this

Role of lipopolysaccharide in the induction of type I interferon-dependent cross-priming and IL-10 production in mice by meningococcal outer membrane vesicles. / Durand, Vanessa; MacKenzie, Joanne; de Leon, Joel; Mesa, Circe; Quesniaux, Valerie; Montoya, Maria; Le Bon, Agnes; Wong, Simon Y C.

In: Vaccine, Vol. 27, No. 13, 18.03.2009, p. 1912-1922.

Research output: Contribution to journalArticle

Durand, Vanessa ; MacKenzie, Joanne ; de Leon, Joel ; Mesa, Circe ; Quesniaux, Valerie ; Montoya, Maria ; Le Bon, Agnes ; Wong, Simon Y C. / Role of lipopolysaccharide in the induction of type I interferon-dependent cross-priming and IL-10 production in mice by meningococcal outer membrane vesicles. In: Vaccine. 2009 ; Vol. 27, No. 13. pp. 1912-1922.
@article{c4b366c9548b4c8186824e3c0e59a447,
title = "Role of lipopolysaccharide in the induction of type I interferon-dependent cross-priming and IL-10 production in mice by meningococcal outer membrane vesicles",
abstract = "We investigated the contribution of lipopolysaccharide (LPS) to adjuvant properties of native outer membrane vesicles (NOMV), a vaccine candidate for meningococcal B disease. NOMV induce the maturation of and cytokine production by murine bone marrow-derived dendritic cells through both toll-like receptors (TLR) 2 and 4 which are mostly dependent on the signalling adaptor MyD88. NOMV are also able to induce B cell proliferation in splenocytes from LPS-hyporesponsive mice. However, induction of IL-10 and type I interferon-dependent, antigen-specific and IFN¿-secreting CD8+ cytotoxic T lymphocyte responses in vivo by NOMV requires LPS. The importance of LPS in the induction of IL-10 and functional cross-priming has implications for NOMV-based vaccine and adjuvant development.",
keywords = "lipopolysaccharide, meningococcal disease, cross-priming",
author = "Vanessa Durand and Joanne MacKenzie and {de Leon}, Joel and Circe Mesa and Valerie Quesniaux and Maria Montoya and {Le Bon}, Agnes and Wong, {Simon Y C}",
year = "2009",
month = "3",
day = "18",
doi = "10.1016/j.vaccine.2009.01.109",
language = "English",
volume = "27",
pages = "1912--1922",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "13",

}

TY - JOUR

T1 - Role of lipopolysaccharide in the induction of type I interferon-dependent cross-priming and IL-10 production in mice by meningococcal outer membrane vesicles

AU - Durand, Vanessa

AU - MacKenzie, Joanne

AU - de Leon, Joel

AU - Mesa, Circe

AU - Quesniaux, Valerie

AU - Montoya, Maria

AU - Le Bon, Agnes

AU - Wong, Simon Y C

PY - 2009/3/18

Y1 - 2009/3/18

N2 - We investigated the contribution of lipopolysaccharide (LPS) to adjuvant properties of native outer membrane vesicles (NOMV), a vaccine candidate for meningococcal B disease. NOMV induce the maturation of and cytokine production by murine bone marrow-derived dendritic cells through both toll-like receptors (TLR) 2 and 4 which are mostly dependent on the signalling adaptor MyD88. NOMV are also able to induce B cell proliferation in splenocytes from LPS-hyporesponsive mice. However, induction of IL-10 and type I interferon-dependent, antigen-specific and IFN¿-secreting CD8+ cytotoxic T lymphocyte responses in vivo by NOMV requires LPS. The importance of LPS in the induction of IL-10 and functional cross-priming has implications for NOMV-based vaccine and adjuvant development.

AB - We investigated the contribution of lipopolysaccharide (LPS) to adjuvant properties of native outer membrane vesicles (NOMV), a vaccine candidate for meningococcal B disease. NOMV induce the maturation of and cytokine production by murine bone marrow-derived dendritic cells through both toll-like receptors (TLR) 2 and 4 which are mostly dependent on the signalling adaptor MyD88. NOMV are also able to induce B cell proliferation in splenocytes from LPS-hyporesponsive mice. However, induction of IL-10 and type I interferon-dependent, antigen-specific and IFN¿-secreting CD8+ cytotoxic T lymphocyte responses in vivo by NOMV requires LPS. The importance of LPS in the induction of IL-10 and functional cross-priming has implications for NOMV-based vaccine and adjuvant development.

KW - lipopolysaccharide

KW - meningococcal disease

KW - cross-priming

U2 - 10.1016/j.vaccine.2009.01.109

DO - 10.1016/j.vaccine.2009.01.109

M3 - Article

VL - 27

SP - 1912

EP - 1922

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 13

ER -